Quick Answer
Esperion Therapeutics, Inc. reported Net Income of -$22.68 million for fiscal year 2025.
Esperion Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$22.68M | +56.2% |
| 2024 | -$51.74M | +75.3% |
| 2023 | -$209.25M | +10.4% |
| 2022 | -$233.66M | +13.2% |
| 2021 | -$269.11M | -87.5% |
| 2020 | -$143.55M | -47.7% |
| 2019 | -$97.17M | +51.9% |
| 2018 | -$201.81M | -20.9% |
| 2017 | -$166.99M | -122.7% |
| 2016 | -$74.98M | -50.6% |
| 2015 | -$49.78M | -36.9% |
| 2014 | -$36.38M | -39.4% |
| 2013 | -$26.09M | -122.2% |
| 2012 | -$11.74M | -8.5% |
| 2011 | -$10.82M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$31.33M | -6.1% | -146.2% |
| June 30, 2025 | -$12.72M | +79.5% | +68.5% |
| March 31, 2025 | -$40.45M | -166.3% | -37.0% |
| September 30, 2024 | -$29.52M | +28.4% | +52.3% |
| June 30, 2024 | -$61.92M | -24.0% | -201.5% |
| March 31, 2024 | $61.02M | +198.9% | +247.9% |
| September 30, 2023 | -$41.25M | +25.2% | +17.4% |
| June 30, 2023 | -$49.94M | +24.7% | +19.1% |
- Esperion Therapeutics, Inc. showed an increase of +56.2% in Net Income compared to the prior fiscal year.
- Over the 2011–2025 period, Esperion Therapeutics, Inc.’s net income has declined by 109.7% (from -$10.82 million to -$22.68 million).
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: